◀ Back to PPP2CA
GSK3B — PPP2CA
Pathways - manually collected, often from reviews:
-
NCI Pathway Database C-MYC pathway:
Axin1/GSK3beta/PIN1/PP2A-B56alpha complex (AXIN1-GSK3B-PIN1-PPP2CA-PPP2R5A)
→
MYC/Max complex (MYC-MAX)
(modification, activates)
Sears et al., Genes Dev 2000, Gregory et al., J Biol Chem 2003, Yeh et al., Nat Cell Biol 2004, Arnold et al., Mol Cell Biol 2006, Arnold et al., EMBO J 2009
Evidence: mutant phenotype, assay, physical interaction
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Lin et al., J Cell Sci 2007
:
We also found that ceramide activated protein
phosphatase 2A (PP2A) indirectly
caused GSK-3beta activation, and that the PP2A regulated PI 3-kinase-Akt pathway was involved in GSK-3beta activation
Qian et al., J Alzheimers Dis 2010
(Alzheimer Disease) :
Inhibition of
PP2A with okadaic acid in metabolically active rat brain slices
caused inhibition of
glycogen synthase kinase-3beta ( GSK-3beta ) via an increase in its phosphorylation at Ser9
Yao et al., Neuroscience 2010
(Memory Disorders) :
ECS also caused tau hyperphosphorylation at multiple Alzheimer related phosphorylation sites with activation of
glycogen synthase kinase-3beta ( GSK-3beta ), Akt and phospho-PKR-like endoreticulum ( PERK ), and
inhibition of protein phosphatase-2A
(PP)-2A